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non–pledget-supported sutures, and (3) systematic use
of a prosthetic ring to compensate for imperfections.
Implantation of a mitral homograft is a complex pro-
cedure necessitating good exposure of the subvalvular
mitral apparatus. Occasionally, anatomic findings such
as severe left ventricular hypertrophy or nondilated and
noncompliant left atrium, which reduce visibility of the
mitral valve, cannot be circumvented, making the pro-
cedure technically impossible. Partial homograft
replacement has been limited and, in our most recent
experience, complete homografts were generally used.2
Due to the variable and unpredictable morphology of
the papillary muscles, their fixation can be easy and
reproducible when the papillary muscles have a single
and narrow head or difficult when bulky or divided into
multiple heads. We have been pleased that there has
been no instance of postoperative papillary muscle
dehiscence. Inspection of the papillary muscles at reop-
eration revealed a remarkable anatomic appearance and
excellent healing of the suture line with endothelializa-
tion and fibrosis.
Since the beginning of our experience, an annuloplas-
ty ring has been systematically inserted at the end of the
procedure. The use of a slightly undersized ring allows
us to compensate for the unavoidable asymmetries in
valvular geometry and to adapt the size of the mitral
orifice to the size of the homograft. In addition, the use
of a prosthetic ring provides an increased surface for
leaflet coaptation, thereby releasing the tension on the
papillary muscle suture line. In this regard, it is inter-
esting to observe that the incidence of papillary muscle
dehiscence was higher in the report by Kumar and asso-
ciates, in which an annuloplasty was performed in only
half of the cases.
As expected, a prosthetic ring reduces the mitral area:
the functional area was measured at 2 to 3 cm2 in our
series2 as compared with 3 to 4 cm2 in Kumar’s series.
It can be concluded that the addition of a prosthetic ring
increases the reliability of the procedure at the price of
a mild reduction in orifice area.
In our experience, the main limitation of the mitral
homograft has been the risk of valve dysfunction due to
a severe mismatch at implantation that could not be cor-
In this issue of the Journal, Kumar and associates1raise a number of important points related to the clin-
ical use of mitral homografts. Their rather negative
results obtained with antibiotic-preserved mitral homo-
grafts need to be carefully analyzed before discarding
this operation which, in my opinion, could be a useful
surgical alternative for the treatment of a particular
subset of patients in whom repair is not possible. At
present, no satisfactory substitute for mitral valve
replacement exists. The morbidity of prostheses is
higher in the mitral than in the aortic position: throm-
boembolic and hemorrhagic complications in the case
of mechanical prostheses and early degeneration in the
case of bioprostheses. Furthermore, exclusion of the
mitral valve apparatus results in changes of left ven-
tricular geometry and impairment of left ventricular
function. Thus, replacement of the mitral valve with a
homograft offers an attractive alternative because it
would avoid the need for permanent anticoagulation,
maintain physiologic flow characteristics, and retain
normal annulopapillary continuity. Nevertheless, to
date the use of mitral homografts has been restricted to
few centers; the difficulty of implantation remains the
main obstacle to their use.
My colleagues and I have been using homograft
mitral valve techniques since 1992,1 and our experience
encompasses 102 patients. The operative technique
included the following characteristics: (1) partial or
total replacement according to the extent of the lesions,
(2) fixation of the donor papillary muscle side to side to
the recipient’s papillary muscle with separated
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and associates that, at present, the mitral homograft is
not yet a standardized procedure to be undertaken rou-
tinely, does not assure success in every case, and is not
applicable to all mitral replacements. The mitral homo-
graft still belongs to the field of clinical research and its
use should not be widespread but limited to a few cen-
ters. An improvement in the method of measuring the
mitral valve is necessary so as to appropriately select
the homograft.
Despite possible refinements in the future, the opera-
tion will certainly remain challenging. If one day the
technical difficulties can be circumvented, as for aortic
homografts, durable results can be expected. Whether
this experience should be continued is answered by the
absence of a satisfactory mitral prosthesis.
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rected with a prosthetic ring. Ignoring or minimizing an
unsatisfactory echocardiographic result will lead to an
early reoperation. This risk might invalidate the indica-
tion for this operation in areas of the world in which a
second procedure cannot be economically afforded by
the patient.
At present, it is difficult to assess the long-term out-
come of mitral homografts due to the bias introduced
by early valve dysfunction. In our experience, normal
valve function was present in 80% of the cases at a 41-
month follow-up period. Reoperation should be imput-
ed to structural deterioration only in those patients
whose initial result was fully satisfactory. In our series,
degeneration of the homograft was identified in only 3
patients. It is widely known that the type of homograft
preservation influences the late outcome: cryopreserva-
tion was used in our series, whereas Kumar’s series
included mainly antibiotic-preserved valves, which
may also account for the differences in results between
the two reports.
Seven years of experience with mitral homografts has
shown that (1) rheumatic etiology could be the prime
indication for this technique, (2) the side-to-side tech-
nique of papillary muscle implantation is reliable, and
(3) the use of a prosthetic ring is necessary to ensure
satisfactory results. However, we agree with Kumar
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